Skip to main content
Clinical Trials/NCT02221141
NCT02221141
Completed
Not Applicable

Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography

Laurence Gabriel1 site in 1 country120 target enrollmentDecember 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Left Ventricular Hypertrophy
Sponsor
Laurence Gabriel
Enrollment
120
Locations
1
Primary Endpoint
Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to determine the prevalence in Belgium of Fabry disease in patients with unexplained hypertrophic cardiomyopathy measured by echocardiography and to determine in Fabry patients which was the most frequently initial symptom.

Actually the early diagnosis is important because a treatment exists that can prevent future complications.

Registry
clinicaltrials.gov
Start Date
December 2013
End Date
April 2021
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Laurence Gabriel
Responsible Party
Sponsor Investigator
Principal Investigator

Laurence Gabriel

Dr Laurence GABRIEL

Centre Hospitalier Universitaire UCLouvain Namur

Eligibility Criteria

Inclusion Criteria

  • unexplained left ventricular hypertrophy

Exclusion Criteria

  • isolated septal hypertrophy

Outcomes

Primary Outcomes

Percentage of patients with left ventricular hypertrophy who have Fabry Disease mutation

Time Frame: 1 day

Study Sites (1)

Loading locations...

Similar Trials